News

The company’s new development direction includes large molecule drugs that will address indications in diabetes and the overall metabolic syndrome. The company’s sub-micron technology allows for development of

Three months after its authorization by the ANSM, the French authority for drug safety, a first patient has been enrolled. Having already successfully completed a Phase I study

Gazyvaro, a new, type II, glycoengineered monoclonal antibody, is marketed as Gazyva outside of the EU and Switzerland. It is designed to attach to CD20, a protein found

The collaboration is aimed at developing new medicines for improved treatment of patients with cardio-metabolic diseases. First agreement between the two companies was signed in June 2011, which

Using GE Healthcare’s single-use WAVE Bioreactor and ReadyToProcess crossflow filtration system, the team developed a new process for the production, clarification and concentration of cytomegalovirus-like particles. Results from

The SwRI technologies employ a controlled and continuous atomizing technology that Flexion believes may facilitate efficient scale-up of Phase III clinical trial material and commercial supply. The company

Once issued, this patent will provide protection in Japan until 2029. The claims under the patent cover composition of matter and methods of use for combining Advaxis’s proprietary

The data were presented in the late-breaking session at the 2014 World Transplant Conference (WTC) in San Francisco, CA by Dr. V. Ram Peddi, Director of Kidney Transplant

"ALPHAEON’s acquisition of PRN brings together world renowned ophthalmologists and a premier physician recommended line of nutriceutical products that benefit patients," said CEO Robert E. Grant. "Over the